IL6 and congenital rubella syndrome: Nevertheless, IL-6 is a critical cytokine in the progression of CRS,[17] tocilizumab is the first-choice treatment for CRS, rapid clinical stabilization is frequently seen with the use of tocilizumab, which strongly implicating cytokines, especially IL-6.[8] Some patients may be refractory to tocilizumab, repeated administration of corticosteroids is the reserved treatment for those patients.